Supernus Pharmaceuticals to Join Neuropsychiatry Summit
Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN) is gearing up for an important virtual event. The company, known for its innovative treatments for central nervous system (CNS) disorders, will have its President and CEO, Jack Khattar, participating in a fireside chat at the TD Cowen's 4th Annual Novel Mechanisms in Neuropsychiatry Summit.
Details of the Event
This significant event is scheduled for a Thursday morning in September. Mr. Khattar's involvement illustrates Supernus Pharmaceuticals' dedication to enhancing the understanding of neuropsychiatric mechanisms. During his talk, he will share insights about the company's impact on developing effective therapies for CNS conditions.
Accessing the Live Webcast and Archive
A live broadcast of Mr. Khattar’s discussion will be available for everyone to view, allowing stakeholders and those interested to learn about the latest advancements in neuropsychiatry. After the live session, an archived version will be posted on the company’s website, where it will remain accessible for 60 days. This ensures that anyone unable to join live can still benefit from the valuable insights shared.
Supernus Pharmaceuticals: Addressing CNS Disorders
As a forward-thinking biopharmaceutical company, Supernus Pharmaceuticals is dedicated to addressing CNS diseases. Their product lineup includes treatments for a variety of conditions, such as epilepsy, migraines, attention-deficit/hyperactivity disorder (ADHD), and more recently, therapies aimed at hypomobility in Parkinson's disease (PD) and chronic sialorrhea.
Innovative Neuroscience Initiatives
With a strong commitment to neuroscience, Supernus is focused on delivering new therapies for patients affected by challenging CNS disorders. Their mission goes beyond simply commercializing existing treatments; they are also exploring new avenues for addressing epilepsy and depression among other critical conditions.
Future Developments in Product Pipeline
The company is actively expanding its pipeline with several novel product candidates aimed at meeting the unmet medical needs within CNS disease treatment. Their dedicated research and development team is currently engaged in clinical trials to test the safety and effectiveness of these new therapies.
Commitment to Community and Stakeholders
Supernus Pharmaceuticals places great importance on nurturing relationships with healthcare professionals, investors, and the wider community. By participating in prominent summits and industry conferences, the company raises awareness about CNS disorders and emphasizes the need for timely and effective treatment options.
Investors and stakeholders looking to learn more about Supernus Pharmaceuticals can find comprehensive information on the company’s official platforms, allowing them to stay informed about the latest updates and insights into their innovative pipeline.
Contact Information
If you have any inquiries, Supernus Pharmaceuticals invites you to reach out to their executive team:
Jack A. Khattar, President and CEO
Timothy C. Dec, Senior Vice President and CFO
Supernus Pharmaceuticals, Inc.
(301) 838-2591
Investor Relations Contact:
Peter Vozzo
ICR Westwicke
(443) 213-0505
peter.vozzo@westwicke.com
Frequently Asked Questions
What does Supernus Pharmaceuticals focus on?
Supernus Pharmaceuticals is dedicated to creating treatments for a range of central nervous system diseases.
Who will represent the company at the summit?
Jack Khattar, the CEO, is set to represent Supernus Pharmaceuticals at the neuropsychiatry summit.
How can I watch the live webcast of the event?
You can access the live webcast on Supernus Pharmaceuticals' website on the day of the summit.
What kinds of diseases does Supernus Pharmaceuticals target?
The company focuses on treating CNS diseases, including epilepsy, migraines, ADHD, and conditions related to Parkinson's disease.
How can I find out more about Supernus Pharmaceuticals?
For detailed information about their products and research pipeline, visit the official website of Supernus Pharmaceuticals.